HROW Stock Forecast & Price Target

Harrow Inc. is well-positioned to leverage the growing market for biosimilars, which has exceeded a 40% market share in certain therapeutic categories, enhancing its potential for revenue growth. The company reported a 22% quarter-over-quarter increase in VEVYE revenue, reaching $22.6 million in Q3 2025, alongside an expanding market share in the dry eye disease segment, achieving a 10.5% share by the end of the same quarter. With projections indicating a potential quarterly revenue run rate exceeding $250 million by Q4 2027, approximately four times higher than Q2 2025 figures, Harrow's strategic positioning and product pipeline instills confidence in long-term revenue and margin expansion.

Harrow Inc faces significant risks that negatively impact its financial outlook, primarily tied to the potential failure of its spinout products to achieve favorable clinical data and secure regulatory approval. Additionally, the company's limited resources may hinder its ability to compete effectively in the market, as it may need to reduce sales and marketing efforts and could require capital raising that may dilute current shareholders. The combination of these factors, along with the uncertainties surrounding market uptake and the potential for unfavorable regulatory changes, casts a shadow on Harrow’s long-term valuation and operational sustainability.